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Lobular carcinoma in situ (LCIS) is considered to be
a risk factor for the development of invasive breast
carcinoma, but it may also be a non-obligate precursor
to invasive lobular carcinoma (ILC). Many LCIS lesions
do not progress to ILC, and the molecular changes
that are necessary for progression from LCIS to ILC
are poorly understood. Disruption in the E-cadherin
complex is the hallmark of lobular lesions, but other
signaling molecules, such as PIK3CA and c-src, are
consistently altered in LCIS. This review focuses on
the molecular drivers of lobular carcinoma, a more
complete understanding of which may give perspective
on which LCIS lesions progress, and which will not, thus
having immense clinical implications.plasia (ALH), a pre-invasive lesion with morphological
features similar to LCIS, except with smaller, less dis-Introduction
Lobular carcinoma in situ (LCIS) has long been consid-
ered a risk factor for the future development, in either
breast, of invasive breast carcinoma (IBC), but recent
evidence suggests that LCIS may also be a non-obligate
precursor to IBC, and more specifically to invasive lobu-
lar carcinoma (ILC).
LCIS is rarely detected by physical examination, nor
does it have specific diagnostic mammographic findings
[1]. Currently about 0.5 to 3.9 % of image-guided core
needle biopsies incidentally identify LCIS and, as mam-
mographic technology improves, the incidence of LCIS
is rising [1, 2]. Patients diagnosed with LCIS have an
8- to 10-fold increased lifetime risk of developing
breast cancer, compared with women without this
diagnosis [3]. The likelihood of developing IBC increases
by about 1 % every year after LCIS diagnosis - with a
13 % risk after 10 years and a 21 to 26 % risk after* Correspondence: mcauliffepf@upmc.edu
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unless otherwise stated.20 years [4, 5]. In a recent subgroup analysis of partici-
pants of the Canadian National Breast Screening Study,
the cumulative probability of subsequent breast cancer
occurrence 5 years after diagnosis was lower for LCIS,
compared with ductal carcinoma in situ (DCIS) (5.7 %
versus 11.4 %, respectively); however, by 20 years after
the diagnosis of LCIS or DCIS, rates of IBC were equiva-
lent (21.3 % and 19 %, respectively) [5].
LCIS was originally described as ‘lobular’ because the
lesions appeared most often in the terminal duct lobular
units (TDLUs), whereas ductal lesions appeared most
often in the mammary ducts. However, it is now under-
stood that all pre-invasive lesions originate from the
TDLUs [6–8] but the terms ‘lobular’ and ‘ductal’ have
persisted.
LCIS is believed to arise from atypical lobular hyper-
tended acini. ALH and LCIS share similar chromosomal
changes and molecular features [9]. Since the factors
that distinguish ALH from LCIS are somewhat subject-
ive [10], the term lobular neoplasia (LN) has been
adopted by many to encompass all pre-invasive lobular
disease. The most well-studied characteristic of LN is
loss of E-cadherin, and this is clinically used to differen-
tiate lobular from ductal lesions [11]. Herein, we review
the studies to date that focus on the molecular mecha-
nisms of LCIS. Gaining a better understanding of the
pathways underlying LCIS and its non-obligate progres-
sion to IBC might allow the development of predictive
tools that would refine the management of this challen-
ging clinical entity.Lobular carcinoma in situ progression
Historically, the concept of LCIS as a non-obligate pre-
cursor of IBC was not well accepted. Foote and Stewart
first coined the term LCIS in 1941, and subsequently
published long-term follow-up of their patients with
LCIS reporting a 20-year cumulative risk of subsequent
carcinoma of 35 % in the ipsilateral and 25 % in the
contralateral breast [12, 13]. In 1978, Haagensen andThis is an Open Access article distributed under the terms of the Creative
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42 years) of 211 patients with LCIS. Of these, 36 (17 %)
patients subsequently developed IBC: 19 in the ipsilat-
eral and 20 in the contralateral breast. In the same year,
Rosen and colleagues [15] published a 24-year follow-up
of 99 patients with LCIS. Thirty-nine breast IBCs oc-
curred in 32 out of 84 patients for whom follow-up was
available. IBC occurred in the ipsilateral breast in 12 pa-
tients, the contralateral breast in 9 patients, bilaterally in
7 patients and unknown in 4 patients. These two studies
posited that it was unlikely that invasive cancer in one
breast progressed from a pre-invasive lesion in the op-
posite breast, and LCIS was, therefore, merely a risk fac-
tor for the development of breast cancer in both breasts.
These results prompted many physicians to assume a
conservative surgical approach to treating patients with
LCIS.
In more contemporary series, however, several studies
have shown a stronger propensity for development of
ipsilateral IBC after diagnosis of LCIS [13, 16]. These
studies, combined with genomic clonality studies com-
paring LCIS and IBC, support a non-obligate precursor
role of LCIS, in addition to being a risk factor for IBC.
Briefly, in 2003, a retrospective study by Page and col-
leagues [17] of 252 women, treated between 1950 and
1985, showed that IBC was 3.1 times more likely to de-
velop in the ipsilateral breast than in the contralateral
breast, after previous diagnosis of ALH. After a previous
diagnosis of LCIS, IBC was two to five times more likely
to develop in the ipsilateral breast [18, 19]. A study
using array comparative genomic hybridization (aCGH)
showed that LCIS is clonally related to synchronous IBC
[20, 21]. Andrade and colleagues [22] also reached this
conclusion comparing single nucleotide polymorphism
(SNP) DNA microarrays of matched LCIS and synchron-
ous lesions. Interestingly, Aulmann and colleagues [23],
using mitochondrial DNA sequencing, identified some
examples of clonality between LCIS and metacronous
IBC (that is, an invasive breast cancer that develops in
the same breast at a later time), although most cases of
later breast cancer were clonally unrelated to the LCIS.
Furthermore, in patients diagnosed with ILC, LCIS is
often found to be closely associated. For example, in a
recent study of 81 patients with ILC, 37 (46 %) had LCIS
that was in close proximity to the invasive component
[24]. We ourselves have frequently observed cases in
which, on careful histological sectioning, there appears
to be myoepithelial layer disruption at discrete foci of
LCIS, accompanied by adjacent ILC, raising the possibil-
ity that these sections are capturing the transition from
in situ to invasive disease (Fig. 1). Together, these studies
support the non-obligate precursor role of LCIS.
Currently, no diagnostic tools exist which can reliably
predict if a woman will subsequently develop IBC afterdiagnosis of LCIS. Most women with LCIS are treated
conservatively, with close observation [1]. Based on the
promising results of the National Surgical Adjuvant
Breast and Bowel Project (NSABP) BCPT P-1 (Breast
Cancer Prevention Trial) and NSABP STAR P-2 (Study
of Tamoxifen and Raloxifene) trial, the most recent
American Society of Clinical Oncology guidelines rec-
ommend that risk-reducing pharmacologic agents, such
as tamoxifen and raloxifene, be discussed with women
diagnosed with LCIS [25–27]. Additional risk factors,
such as strong family history and very young age, may
prompt prophylactic bilateral mastectomy, but this is
pursued in only a minority of women with this diag-
nosis [28].
Classification of lobular carcinoma in situ
Currently, histological features guide classification of LCIS
lesions. The three main histological sub-classifications of
LCIS are classical (CLCIS), florid (FLCIS) and pleomorphic
(PLCIS), and these entities can be found to coexist.
Histologically, CLCIS is characterized by a mono-
morphic population of small round cells with a ring of
clear cytoplasm [29]. Cells within the lesion are loosely
adherent, filling the lumen of the acini and distending
the TDLU, yet they maintain the architecture of the lob-
ules with an intact basement membrane and myoepithe-
lial cell layer [30]. Mitotic figures and necrosis, as well
as calcifications, are not common in CLCIS. Pagetoid
spread, in which neoplastic cells extend along the mam-
mary ducts, is frequently observed. There are two cat-
egories of CLCIS, type A and type B [31]. Type A CLCIS
is generally low grade, with small nuclei and inconspicu-
ous nucleoli. Type B CLCIS is composed of cells with
larger nuclei and small nucleoli. CLCIS tends to be posi-
tive for estrogen receptor (ER) and progesterone recep-
tor (PR), and negative for HER2.
FLCIS is a comparatively more rare lesion, histologi-
cally characterized by massive expansion of the involved
TDLUs, often associated with necrosis and calcifications.
Morphologically, it resembles solid-type DCIS. The le-
sion is frequently associated with ILC, supporting FLCIS
as a precursor of ILC [32]. FLCIS shows more genetic
instability than CLCIS, including a higher fraction of
genomic alterations and breakpoints [33].
PLCIS is a subtype of LCIS that is commonly associ-
ated with pleomorphic ILC and that tends to be higher
grade [29, 34–36]. In contrast to CLCIS and FLCIS, the
nuclei and nucleoli in PLCIS are larger, and cells have
more abundant cytoplasm. Calcifications and comedo-
type necrosis are more common in PLCIS than in
CLCIS. PLCIS can be divided into apocrine or non-
apocrine PLCIS, based on the presence or absence, re-
spectively, of eosinophilic granules in the cytoplasm,
intracytoplasmic vacuoles and vesicular chromatin [31].
Fig. 1 Lobular carcinoma in situ in association with invasive lobular carcinoma. Histological sections from multiple patients capture areas of
lobular carcinoma in situ (LCIS) that appear to have focal myoepithelial layer disruption adjacent to invasive lobular carcinoma (ILC), suggesting
possible progression of LCIS to ILC at such transitions. Green hatched lines mark the myoepithelial layer; orange arrows are possible foci of
myoepithelial disruption; yellow arrows highlight invasive cells. In addition to the cells marked by yellow arrows, additional ILC cells are present in
each image throughout the stroma, surrounding the areas of LCIS
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reactivity to GCDFP-15, a protein originally isolated
from breast cystic fluid and shown to be highly
expressed in cancers associated with salivary glands,
sweat glands, and prostate [35, 37]. The apocrine variant
of PLCIS is shown to have more genetic instability, and
it is the most likely to have amplified HER2 [31, 34].
Interestingly, aCGH-based data suggest that FLCIS has
more genomic alterations than PLCIS as a group, but
less genetic complexity than apocrine PLCIS [33].
Beyond the most common type A CLCIS, classification
of LCIS is difficult and can be somewhat subjective, es-
pecially in the setting of higher nuclear grade, presence
of calcifications, necrosis and/or unusal ER or HER2 sta-
tus. There is also controversy regarding treatment of
FLCIS and PLCIS. PLCIS is usually treated more aggres-
sively, with surgery including re-excision to negative
margins and often with radiation therapy, as well as with
endocrine therapy. However, there are limited data to
support clinical decision making for these entities.
An alternative classification system for LCIS was de-
veloped by Bratthauer and Tavassoli [38]. This classifica-
tion uses the term lobular intraepithelial neoplasia (LIN)or LN in lieu of ALH and LCIS. Some opine that LIN
grading is better because it removes the term ‘carcinoma’,
which can be a confusing term in the context of in situ
disease [39]. LIN is divided into three grades. LIN1
corresponds to ALH lesions where the lumen is filled,
but the acini are not distended. LIN2 lesions have
acini that are distended but not fused, corresponding
to CLCIS lesions. LIN3 describes more advanced LCIS
with marked distention of the lobules, including FLCIS
and PLCIS.
Sub-classifying LCIS, whether by histology or by LIN
grade, has been useful for identifying lesions more likely
to progress so that they may be treated more aggres-
sively [40]. Clearly, improving our understanding of mo-
lecular drivers of LCIS progression will be an important
way to improve our ability to differentiate aggressive
from benign premalignant lesions and further personalize
treatment recommendations for patients.
Molecular characteristics of lobular carcinoma
in situ
In contrast to the role of LCIS as a risk factor for the de-
velopment of breast cancer, a role for direct progression
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the molecular basis is currently poorly understood. LCIS
must traverse myoepithelial cells and the basement
membrane in order to invade locally. Schematically
shown in Fig. 2 are four proposed mechanisms that
could influence this process, and that are likely not
mutually exclusive. Cells may acquire genetic (and/or
epigenetic) changes in critical pathways that allow mi-
gration into the stroma. Alternatively, or in concert, cells
may receive signals that cause progression from the
stroma, including fibroblasts, adipocytes, and immune
cells. Another possibility is that tumor suppressive
myoepithelial cells may become compromised, allowing
LCIS cells to break through and gain access to the
stroma. Finally, enlarging LCIS cellular density may
cause physical strain on the myoepithelial cells and base-
ment membrane such that the cells may physically rupture
a lobule. It is most likely that the progression of LCIS to
IBC occurs through a combination of these events.
To better identify LCIS lesions that may progress ver-
sus those that remain dormant requires a thorough
knowledge of the mechanisms that drive progression to
invasive disease. Current research on LCIS has focused
on four main areas: (1) prognostic markers, (2) genomic
changes, (3) factors related to epithelial to mesenchymal
transition (EMT), and (4) signaling pathways. We
summarize and discuss those areas of research below.
Prognostic markers
The expression of nuclear receptors - especially ER - can
be used to predict clinical outcome of tumors [41, 42];
80 to 100 % of LCIS cases express ERα, most of which
show moderate to strong immunoreactivity by immuno-
histochemistry [43–46] (Table 1). Similarly, ILC is also a
highly ER-positive disease, with greater than 90 % ERFig. 2 Proposed mechanisms of lobular carcinoma in situ progression to in
invasive breast cancer may be influenced by multiple factors, including cel
with the microenvironment, changes within the myoepithelial cells (MEPs),
by LCIS within the lobule, causing cells to rupture the lobule. ILC, invasivepositivity [47, 48]. Some aggressive variants of LCIS are
more likely to be ER-negative. For example, 80 % of apo-
crine PLCIS lesions are ER-negative [49]. This suggests
that ER-negativity in LCIS may be a potential marker of
progression of more aggressive lesions. However, be-
cause most CLCIS and many PLCIS lesions are ER-
positive, additional prognostic markers are clearly
needed to better differentiate ER-positive lesions that
will progress versus those that will not.
Expression of PR is regulated by ER and is considered
a prognostic marker of IBC [50]. Loss of PR expression
is associated with endocrine resistance [51], and luminal
B tumors are more often PR-negative/low compared to
less aggressive luminal A tumors. Approximately 47 to
90 % of LCIS lesions express PR. However, the expres-
sion of PR is lower in LCIS lesions associated with IBC
[43–46], and in apocrine PLCIS [31], implying that PR-
low lesions are more likely to progress to invasive cancer
[52]. Intriguingly, a recent study showed an inverse rela-
tionship between ER/PR status and Ki67 proliferation
rate in ductal cancer but not in lobular cancer, such that
ER-negative status did not correlate with high Ki67 in
invasive lobular cancers whereas it did with invasive
ductal cancers [52]. However, this has not yet been stud-
ied in detail in LCIS.
In contrast to ERα, the role of ERβ1 and the spliced
variant ERβ2 in breast cancer is less well understood
[53]. Some hypothesize that tamoxifen is an agonist of
ERβ [54], thus suggesting that ERβ could be a marker of
poor prognosis, due to its ability to oppose the anti-
proliferative effects of tamoxifen-binding ERα. Recently,
Huang and colleagues [55] measured ERβ expression in
DCIS, invasive ductal cancer (IDC), and ILC. They con-
cluded that while ERβ expression is high in normal
mammary epithelial cells, ERβ expression is low in DCISvasive breast cancer. Progression of lobular carcinoma in situ (LCIS) to
l-intrinsic changes, such as mutations, extrinsic factors from interaction
and physical strain on the basement membrane components, exerted
lobular carcinoma
Table 1 Common prognostic markers in classical lobular
carcinoma in situ
Reference n ERα (%) PR (%) c-erbB-2 (%)
Rudas et al. 1997 [46] 23 80 90 4
Fisher et al. 1998 [26] 15 100 100 0
Querzoli et al. 1998 [45] 19 100 47 11
Mohsin et al. 2005 [44] 57 98 84 4
Chen et al. 2009 [49] 21 100 100 0
Green et al. 2009 [43] 47 100 100
Vincent-Salomon et al. 2012 [59] 58 91 66
Morrogh et al. 2012 [77] 11 100 100 0
ER estrogen receptor, PR progesterone receptor
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of ERβ, with a reduction in expression in late stage ILC.
LCIS samples were not included in this study. Results
from an earlier study showed that LCIS has higher ERβ2
expression compared with normal epithelium, but that
ERβ1 expression is not different [43]. Huang and col-
leagues concluded that the spliced variant ERβ2 is an in-
dicator of hypoxia, not malignancy, which may explain
the increased ERβ2 spliced variant in LCIS [43, 55]. In
contrast to this observation, Nonni and colleagues [56]
showed that ERβ expression in LN is significantly lower
than in normal epithelium, although this study had a
smaller sample size (n = 30).
Amplification of c-erbB-2 (HER2) is a marker of poor
prognosis in patients with IBC. Fortunately, anti-HER2
antibodies have been effective drugs for HER2-positive
tumors [57]. Understanding expression levels of HER2
in LCIS may shed light on its malignant nature. In LCIS,
0 to 11 % of tumors have HER2 amplification (Table 1).
More aggressive LCIS subtypes are more likely to have
amplified HER2 [44, 45]; 18 % of FLCIS and 31 % of
apocrine PLCIS show HER2 amplification [33, 49].
Ki-67 expression is a marker of the proliferation rate
of a tumor, and higher proliferative rates correlate with
poor clinical outcomes [58]. In many LCIS lesions, Ki-67
expression is very low, corresponding to a 0 to 2 % pro-
liferation rate in some studies [44, 45]. Other studies
have shown that some LCIS lesions express a higher
than 10 % proliferation rate [59]. Patients who have
LCIS with higher proliferation rates may have a higher
probability of relapse after surgery [59]. Currently, how-
ever, Ki67 is not used clinically to guide management
decisions for LCIS.
The tumor suppressor gene encoding p53 is often
dysregulated in human cancers [60]. In LCIS, p53
overexpression (reflecting protein stabilization as result
of mutation) has been shown to be relatively low, ranging
from 0 to 19 % using immunohistochemistry [44, 46].
Although the mutation rate of the p53 gene has not beenassessed for LCIS, loss of heterozygosity has been ob-
served for chromosome 17p, which is the location of the
gene that encodes p53.
Recently, in a study by Andrade and colleagues, 23
patient-matched samples of normal breast tissue, LCIS,
and ILC were subjected to microarray analysis to deter-
mine which genes might be involved in the progression
of LCIS [61]. They identified 169 candidate genes in-
volved in LCIS progression. The same study also showed
that 40 CLCIS patient samples clustered in two groups,
suggesting heterogeneity between CLCIS lesions at the
transcriptomic level, even if they may otherwise appear
homogenous.
The prognostic markers mentioned above do not reli-
ably and accurately predict the potential of LCIS lesions
to progress to invasive disease. Therefore, there is a crit-
ical need to identify better markers of progression,
which might be used clinically to guide management.
Genomic changes
Much of what is known about LCIS has been generated
from studies utilizing aCGH. These studies, and others,
suggest that LCIS and ILC are genetically similar and
clonally related [20, 22, 23, 34, 62]. aCGH studies have
also revealed similarities between lobular lesions and
other low-grade lesions, including flat epithelial atypia,
atypical ductal hyperplasia, low-grade DCIS and low
grade IDC [34, 63, 64]. In light of these data, some have
proposed that a broadly defined low-grade family of breast
neoplasia exists, which has similar molecular drivers dur-
ing disease progression [65, 66]. Characterization of breast
cancer subtypes using gene expression profiling and DNA
copy number variation has led to depiction of HER2-
positive and ‘triple negative’ breast cancers as part of a
‘high-grade pathway’ and certain low-grade ER/PR-positive
breast cancers as part of the ‘low-grade pathway’ [67]. Re-
cently, this ‘low-grade precursor hypothesis’ has been chal-
lenged, with evidence that LCIS can progress into both
low-grade and high-grade tumors [22, 67] and that LCIS
can be a precursor to both ILC and IDC [62].
Specific chromosomal alterations are found frequently
and consistently in LCIS. The chromosomal changes
most commonly associated with LCIS are loss of 16q
and gain of 1q [34]. Chromosome 16q contains several
tumor suppressor genes, including E-cadherin (CDH1),
a member of the calcium-dependent adhesion family of
transmembrane proteins. Loss of other genes on 16q,
including those encoding dipeptidase 1 (DPEP1) and
CCCTC-binding factor (CTCF), have also been implicated
in ILC [34, 68]. Loss of chromosome 16q, combined with
mutations often resulting in premature stop codons and
thus truncated proteins, transcriptional repression,
and possibly gene promoter methylation, can lead to
biallelic inactivation of CDH1. In addition to the 16q- and
Table 2 Mechanisms of E-cadherin loss
Reference Mechanism Sample
size
Percentage
E-cadherin loss
Vos et al. 1997 [97] LOH 7 86 %
Palacios et al. 2003 [98] LOH 7 100 %
Sarrió et al. 2003 [99] LOH 9 100 %
Mastracci et al. 2005 [100] LOH 13 15 %
Vos et al. 1997 [97] Mutation 2 100 %
Rieger-Christ et al. 2001 [101] Mutation 21 38 %
Sarrió et al. 2003 [99] Mutation 3 100 %
Mastracci et al. 2005 [100] Mutation 14 100 %
Sarrió et al. 2003 [99] Methylation 9 11 %
Morrogh et al. 2012 [77] Transcription 36 100 %
LOH loss of heterozygosity
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morphic) lesions demonstrate loss of 17p, which maps the
gene encoding p53 [33]. Loss or amplification of 11q
(containing the cyclin D1 gene) and loss of 8p are seen
with a higher incidence in PLCIS compared with CLCIS.
Furthermore, some FLCIS harbor amplification of 17q
(spanning the gene encoding HER2), a finding seen less
commonly in CLCIS [33]. Losses of 16p, and gains of 6q
are also sometimes observed in LCIS [9]. Amplification
of 16p and losses of 3q, 11q and 13q have also been de-
scribed [49]. Results of aCGH experiments have shown
that while most chromosomal changes in LCIS are not
consistent, those that are most consistent (namely, 16q
loss and 1q amplification) are found early in the progres-
sion to invasive disease. Although this information can
be helpful for determining the relatedness of different
lesions, it is less likely to be helpful clinically in distin-
guishing LCIS lesions that will progress from those that
will not. Employing modern genomic techniques, such as
next generation sequencing, will be critical in expanding
our understanding of the genetic changes involved in the
progression of LCIS.
LCIS is often multicentric, sometimes arising from 10
or more foci [69], and bilateral LCIS is also common.
Furthermore, according to one study, about 23 % of
women who develop LCIS have at least one first-degree
relative with IBC [70]. Consistent genomic changes in
LCIS may shed light on the genetic inheritance of the
disease. There is evidence that germline polymorphisms
in the CDH1 gene (E-cadherin) predispose women to
LCIS [71], and LCIS was also found in some patients
with CDH1-related hereditary diffuse gastric cancer
syndrome [72].
Recently, Sawyer and colleagues [73] analyzed SNPs in
a total of 6539 lobular cancers, including 436 cases of
pure LCIS, to identify those which specifically predis-
posed women to lobular disease. This study, which is
part of GLACIER, a UK study of lobular breast cancer,
utilized the iCOGS chip, a custom SNP array that com-
prises 211,155 SNPs enriched at predisposition loci for
breast and other cancers [74]. Six SNPs were found that
were strongly associated with ILC and LCIS, but not
with IDC, with rs11977670 (7q34) showing the strongest
association. Preliminary data in this study suggest that
this SNP may influence levels and/or activity of
JHDM1D, or SLC37A3, proteins with histone demethy-
lase and sugar-phosphate exchanger functions, respect-
ively. It is also possible that this SNP interacts with
expression or function of the nearby BRAF gene, or
that it controls expression of other non-coding genes.
ENCODE data show overlap of the SNP with an area of
H3K27 acetylation, supporting a role of this region in
gene regulation. A SNP in LGR6 (rs6678914) showed
specific associations with LCIS, and not with ILC.Similarly, other variants had stronger effect sizes in LCIS
compared with ILC - for example, SNPs at TOX3,
ZNF365 and MLLT10 loci. There were also SNPs that
were more strongly associated with ILC compared with
LCIS, including variants in the FGFR2 and MAP3K1
genes. Intriguingly, none of the 56 CDH1 SNPs present
on the iCOGS chip showed significant association with
lobular cancer. This study provided an outstanding start-
ing point for further functional studies of the identified
pathways, especially to decipher their roles in develop-
ment and progression of LCIS.
Epithelial to mesenchymal transition markers in lobular
carcinoma in situ
EMT is a process by which epithelial cells gain charac-
teristics of mesenchymal cells, thereby promoting motil-
ity through tissue stroma [75, 76]. It has been proposed
to be an essential step in breast cancer progression and
metastasis. A critical component of EMT is the reduced
function of cell-cell junctions, and it is feasible that
EMT could also play a role in the development of LCIS,
which is characterized by decreased cohesiveness within
the lobule. Decreased expression of E-cadherin and dis-
sociation of the cadherin-catenin complex is both a ne-
cessary step of EMT and a hallmark of lobular disease.
E-cadherin loss and accumulation of cytosolic p120 ca-
tenin are frequently used diagnostically to differentiate
between lobular and ductal lesions [11, 77]. A combin-
ation of mechanisms has been shown to contribute to
the loss of E-cadherin, including somatic mutations,
chromosomal loss, epigenetic silencing, and transcrip-
tional repression (Table 2). The tight junction protein
claudin 4, which plays a role in loss of cellular adhesion
during EMT, was also shown to be downregulated in
LCIS compared with normal tissue [78], and might thus
also contribute to the decrease in cellular adhesion in
lobular disease.
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scription factors, such as SNAIL, SLUG, TWIST, and
ZEB1, and by paracrine signaling molecules, including
TGF-β and Wnt [76, 77, 79, 80]. In a subset of LCIS,
some EMT genes, such as TWIST, are expressed [77, 81].
There is some evidence that in normal epithelial tissues,
TWIST is epigenetically silenced through hypermethyla-
tion of its promoter region and its overexpression in
LCIS is at least in part a result of hypomethylation [81].
TWIST expression is increased even more so in ILC [77],
and high expression of ZEB1 was reported in poorly dif-
ferentiated ILC [79, 80]. Thus, TWIST and ZEB1 may
play a role in the development of ILC by promoting EMT
through two major steps: dissociation of cell junctions
with loss of polarity, and cytoskeletal changes that
promote motility [76]. Another aspect of EMT involves
cytoskeletal changes and increased motility [76]. Rho-
GTPases control actin remodeling and are regulated by
p120 catenin [82]. With the accumulation of cytosolic
p120 catenin in lobular cancer, it is not surprising that
p120 appears to be a major driver of the lobular pheno-
type [83]. LCIS cells demonstrate an affinity to interact
with extracellular matrix components by increasing mes-
enchymal surface molecules like N-cadherin [84] and
laminin receptor 1 [85]. Matrix metalloproteinase 9, well
known to cause degradation of extracellular matrix to
promote migration into stroma, was shown to be highly
expressed in LCIS compared with normal mammary epi-
thelium [78]. Collectively these data suggest the early
LCIS lesions are poised for invasion; however, most will
not progress to invasive disease.
Activation of other signaling pathways in lobular
carcinoma in situ
Several signaling pathways are commonly altered in
lobular cancer. Perhaps most frequently, PIK3CA acti-
vating point mutations, long implicated in tumorigen-
esis, are found in both in situ and invasive lobular [86,
87]. In fact, in one study, 44 % (7 of 16 cases) of lobular
neoplasias harbored activating PIK3CA mutations. Such
mutations are also found in ductal cancers, and are not
unique to breast carcinoma. As a comparison, these point
mutations were found in 10 out of 21 (48 %) cases of DCIS
and 13 out of 37 (35 %) invasive carcinomas [86].
Similarly to a variety of cancers, c-Src was found to be
activated in both LCIS and ILC. Interestingly, some c-
Src downstream targets such as Fak and Stat-3 were only
active in ILC, but not in pre-invasive lobular neoplasia
[84, 88]. Such activation thus represents a possible
switch to allow LCIS cells to invade. In addition to Stat3,
there is also some evidence for Stat5a playing a potential
role in LCIS development and progression [89]. Stat5 is
an important signaling molecule in the development of
normal milk-producing mammary cells, and providessurvival signals to mammary epithelial cells during lacta-
tion [90]. There is also evidence that increased Stat5
levels prevent apoptosis normally initiated by oncopro-
teins and involution [91]. Bratthauer and colleagues [89]
reported strong staining for STAT5a in normal mammary
epithelial cells, but loss in DCIS and IDC. Intriguingly,
LCIS and ILC lesions retained STAT5 expression in 32 %
and 17 % of the samples, respectively [89]. Amplification
of prolactin receptor - an upstream activator of STAT5a
signaling in breast tissue - is also observed in LCIS and
ILC lesions, but not in DCIS lesions [92, 93]. These data
suggest that STAT5a might provide survival signals to
neoplastic cells in LCIS.
And finally, there is a report showing that
cyclooxygenase-2 (COX-2) localizes within calveolae-like
structures in the membrane, especially in more low-
grade lesions [94, 95]. COX-2 expression has been impli-
cated in the development of cancers by promoting an
inflammatory environment conducive to tumor develop-
ment [96] and, despite limitations, COX-2 inhibition
may hold promise for cancer therapy and prevention.
Further studies are necessary to understand the role of
COX2, and in more general the role of the immune en-
vironment on development and progression of LCIS.
Conclusion
LCIS is a clinically significant lesion which is incom-
pletely understood and vastly understudied. Histological
characteristics are the current standard for determining
likelihood of progression of LCIS to IBC. It is likely that
certain patients are either under- or overtreated. There
is a critical need for better predictors of progression to
invasive disease. The key to determining whether a LCIS
lesion will progress will lie in the molecular characteris-
tics of the lesion, including genetic aberrations in im-
portant signaling pathways, and alterations in EMT
pathways. Since there are currently no models available
to study LCIS, the generation of in vitro and in vivo
model systems faithfully recapitulating the disease
should be a focus of ongoing and future studies. A deeper
understanding of the drivers of LCIS toward progression
to invasive cancer may illuminate possible diagnostic tar-
gets that can allow clinicians to differentiate benign pre-
invasive lesions from potentially malignant ones.
Note
This article is part of a series on Lobular breast cancer,
edited by Ulrich Lehmann. Other articles in this
series can be found at http://breast-cancer-research.
com/series/LBC.
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